体内
体外
癌症研究
细胞生长
食管鳞状细胞癌
癌
化学
生物
医学
病理
生物化学
生物技术
作者
Xinning Liu,Yanan Jiang,Hao Zhou,Xiaokun Zhao,Mingzhu Li,Zhuo Bao,Zitong Wang,Chenyang Zhang,Zhenliang Xie,Jimin Zhao,Zigang Dong,Kangdong Liu,Zhiping Guo
标识
DOI:10.1038/s41419-023-05633-2
摘要
Esophageal squamous cell carcinoma (ESCC) is an upper gastrointestinal cancer with high morbidity and mortality. New strategies are urgently needed to prolong patients' survival. Through screening FDA-approved drugs, we found dasabuvir, a drug approved for hepatitis C virus (HCV) treatment, suppressed ESCC proliferation. Dasabuvir could inhibit the growth of ESCC cells in a time and dose-dependent manner and arrested cell cycle at the G0/G1 phase. The antitumor activity was further validated in vivo using patient-derived xenograft tumor models. In terms of mechanism, we unveil that dasabuvir is a Rho-associated protein kinase 1 (ROCK1) inhibitor. Dasabuvir can bind to ROCK1 and suppress its kinase activity, thus downregulating the phosphorylation of ERK1/2 by ROCK1 and the expression of cyclin-dependent kinase 4 (CDK4) and cyclin D1. These results provide evidence that dasabuvir suppresses ESCC growth in vivo and in vitro through blocking ROCK1/ERK signaling pathway.
科研通智能强力驱动
Strongly Powered by AbleSci AI